AstraZeneca’s Camizestrant Clears India’s SEC Review
The Story:
AstraZeneca’s camizestrant has received a positive SEC recommendation in India for HR-positive, HER2-negative advanced breast cancer with ESR1 mutations, with a local Phase III trial waived.
The Take:
The recommendation moves camizestrant closer to potential Indian approval, strengthening AstraZeneca’s precision oncology portfolio, subject to final regulatory clearance and post-marketing surveillance requirements.
Granules India Plans ₹2,000 Crore Investment in Higher-Value Pharma
The Story:
Granules India plans to invest around ₹2,000 crore over the next 3–4 years to expand complex generics, oncology, peptide CDMO, R&D and US operations.
The Take:
The investment accelerates Granules’ shift toward higher-value products, with first-to-file US generics and peptide CDMO expansion offering additional growth opportunities.
Lupin Launches Triple-Combination MDI for COPD in India
The Story:
Lupin has launched Formoflo-G MDI in India after DCGI approval, combining glycopyrronium, formoterol and fluticasone in a twice-daily inhaler for long-term management of moderate to severe COPD.
The Take:
The launch strengthens Lupin’s respiratory portfolio with a differentiated triple-combination therapy that could improve treatment convenience and expand its presence in India’s COPD market.
